Evidence map›Paper›PMID 35572397›Full record

ArticleJournal of advanced research2022

Calix[

Leonardo da Silva Neto, Angélica Faleiros da Silva Maia, Adriana Martins Godin, Paulo Sérgio de Almeida Augusto, Raissa Lima Gonçalves Pereira, Sordaini Maria Caligiorne, Rosemeire Brondi Alves, Simone Odília Antunes Fernandes, Valbert Nascimento Cardoso, Gisele Assis Castro Goulart and 4 more

Open access · goldAbstract read
In one paragraph

Article in Journal of advanced research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Leonardo da Silva NetoDepartment of Chemistry, Institute of Exact Sciences, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil.
Angélica Faleiros da Silva MaiaDepartment of Chemistry, Institute of Exact Sciences, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil.
Adriana Martins GodinDepartment of Chemistry, Institute of Exact Sciences, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil.
Paulo Sérgio de Almeida AugustoDepartment of Mental Health, Universidade Federal de Minas Gerais, Belo Horizonte 30130-100, MG, Brazil.
Raissa Lima Gonçalves PereiraDepartment of Mental Health, Universidade Federal de Minas Gerais, Belo Horizonte 30130-100, MG, Brazil.
Sordaini Maria CaligiorneDepartment of Mental Health, Universidade Federal de Minas Gerais, Belo Horizonte 30130-100, MG, Brazil.
Rosemeire Brondi AlvesDepartment of Chemistry, Institute of Exact Sciences, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil.
Simone Odília Antunes FernandesDepartment of Clinical & Toxicological Analysis, Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil.
Valbert Nascimento CardosoDepartment of Clinical & Toxicological Analysis, Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil.
Gisele Assis Castro GoulartDepartment of Pharmaceutics, Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil.
Felipe Terra MartinsInstitute of Chemistry, Universidade Federal de Goiás, Goiânia 74690-900, MG, Brazil.
Maila de Castro Lourenço das NevesDepartment of Mental Health, Universidade Federal de Minas Gerais, Belo Horizonte 30130-100, MG, Brazil.
Frederico Duarte GarciaDepartment of Mental Health, Universidade Federal de Minas Gerais, Belo Horizonte 30130-100, MG, Brazil.
Ângelo de FátimaDepartment of Chemistry, Institute of Exact Sciences, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil.
Universidade Federal de Minas Gerais · BRUniversidade Federal de Goiás · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Cocaine use disorder is a significant public health issue without a current specific approved treatment. Among different approaches to this disorder, it is possible to highlight a promising immunologic strategy in which an immunogenic agent may reduce the reinforcing effects of the drug if they are able to yield sufficient specific antibodies capable to bind cocaine and/or its psychoactive metabolites before entering into the brain. Several carriers have been investigated in the anti-cocaine vaccine development; however, they generally present a very complex chemical structure, which potentially hampers the proper assessment of the coupling efficiency between the hapten units and the protein structure. Objectives: The present study reports the design, synthesis and preclinical evaluation of two novel calix[ Methods: The preclinical assessment corresponded to the immunogenicity and dose-response evaluation of Results: Both calix[ Conclusion: The present results demonstrate the potential of

Indexed as

CalixarenesCocaineVaccinesAnimalsHaptensTissue DistributionCalixarenesCocaineHaptensVaccinesCalixarenesChemical addictionCocaineCrackImmunotherapyTRODAT-1

Identifiers

PMID35572397
PMCPMC9091763
OpenAlexW3199836519

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.